Literature DB >> 35136336

Pembrolizumab-Induced Type 1 Diabetes in a 95-Year-Old Veteran With Metastatic Melanoma.

Damond B Ng1, Jane Weinreb1,2, Sara-Megumi Rumrill3,4.   

Abstract

Low C-peptide levels should prompt a high suspicion for immune checkpoint inhibitor-induced type 1 diabetes, and initiation of insulin therapy should be strongly considered.
Copyright © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Entities:  

Year:  2021        PMID： 35136336      PMCID： PMC8815611          DOI： 10.12788/fp.0191

Source DB:  PubMed          Journal:  Fed Pract        ISSN： 1078-4497


  20 in total

Review 1.  Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Authors:  David J Byun; Jedd D Wolchok; Lynne M Rosenberg; Monica Girotra
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

Review 2.  Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.

Authors:  Katrien Clotman; Katleen Janssens; Pol Specenier; Ilse Weets; Christophe E M De Block
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

3.  Endocrinopathies with use of cancer immunotherapies.

Authors:  Natalie M Villa; Abtin Farahmand; Lin Du; Michael W Yeh; Stephanie Smooke-Praw; Antoni Ribas; Bartosz Chmielowski; Grace Cherry; Angela M Leung
Journal:  Clin Endocrinol (Oxf)       Date:  2017-10-09       Impact factor: 3.478

4.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

5.  A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.

Authors:  Jeroen de Filette; Corina Emilia Andreescu; Filip Cools; Bert Bravenboer; Brigitte Velkeniers
Journal:  Horm Metab Res       Date:  2019-03-12       Impact factor: 2.936

6.  Fructosamine is a useful indicator of hyperglycaemia and glucose control in clinical and epidemiological studies--cross-sectional and longitudinal experience from the AMORIS cohort.

Authors:  Håkan Malmström; Göran Walldius; Valdemar Grill; Ingmar Jungner; Soffia Gudbjörnsdottir; Niklas Hammar
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

7.  Evaluation of agreement between hemoglobin A1c, fasting glucose, and fructosamine in Senegalese individuals with and without sickle-cell trait.

Authors:  Sarah Skinner; Mor Diaw; Maïmouna Ndour Mbaye; Philippe Joly; Céline Renoux; Céline Masson; Charlotte Cuerq; Philomène Lopez; Malick Ndour; Demba Diedhiou; Djiby Sow; Saliou Diop; Abdoulaye Samb; Vincent Pialoux; Philippe Connes
Journal:  PLoS One       Date:  2019-02-15       Impact factor: 3.240

8.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

Authors:  Romualdo Barroso-Sousa; William T Barry; Ana C Garrido-Castro; F Stephen Hodi; Le Min; Ian E Krop; Sara M Tolaney
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

9.  Reporting of Immune Checkpoint Inhibitor Therapy-Associated Diabetes, 2015-2019.

Authors:  Jiaqing Liu; Huaqiang Zhou; Yaxiong Zhang; Wenfeng Fang; Yunpeng Yang; Yan Huang; Li Zhang
Journal:  Diabetes Care       Date:  2020-05-11       Impact factor: 19.112

10.  Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.

Authors:  Muhammad Zubair Afzal; Rima R Mercado; Keisuke Shirai
Journal:  J Immunother Cancer       Date:  2018-07-02       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.